Faculty Opinions recommendation of Differential gene expression in response to transforming growth factor-beta1 by fetal and postnatal dermal fibroblasts.

2007 ◽  
Author(s):  
Stephen Schwartz
Keyword(s):  
Gene Expression ◽  
Growth Factor ◽  
Differential Gene Expression ◽  
Transforming Growth Factor ◽  
Dermal Fibroblasts ◽  
Transforming Growth Factor Beta1 ◽  
Differential Gene

Regulation and consequences of differential gene expression in diabetic kidney disease

2008 ◽  
Vol 36 (5) ◽  
pp. 941-945 ◽  
Author(s):  
Madeline Murphy ◽  
John Crean ◽  
Derek P. Brazil ◽  
Denise Sadlier ◽  
Finian Martin ◽  
...  
Keyword(s):  
Gene Expression ◽  
Growth Factor ◽  
Differential Gene Expression ◽  
High Glucose ◽  
Transforming Growth Factor ◽  
Tissue Growth ◽  
Tubulointerstitial Fibrosis ◽  
In Vivo Models ◽  
Differential Gene

DN (diabetic nephropathy) is the leading cause of end-stage renal disease worldwide and develops in 25–40% of patients with Type 1 or Type 2 diabetes mellitus. Elevated blood glucose over long periods together with glomerular hypertension leads to progressive glomerulosclerosis and tubulointerstitial fibrosis in susceptible individuals. Central to the pathology of DN are cytokines and growth factors such as TGF-β (transforming growth factor β) superfamily members, including BMPs (bone morphogenetic protein) and TGF-β1, which play key roles in fibrogenic responses of the kidney, including podocyte loss, mesangial cell hypertrophy, matrix accumulation and tubulointerstitial fibrosis. Many of these responses can be mimicked in in vitro models of cells cultured in high glucose. We have applied differential gene expression technologies to identify novel genes expressed in in vitro and in vivo models of DN and, importantly, in human renal tissue. By mining these datasets and probing the regulation of expression and actions of specific molecules, we have identified novel roles for molecules such as Gremlin, IHG-1 (induced in high glucose-1) and CTGF (connective tissue growth factor) in DN and potential regulators of their bioactions.

scholarly journals Leukoregulin down-regulates type I collagen mRNA levels and promoter activity in human dermal fibroblasts, and counteracts the up-regulation elicited by transforming growth factor-β

1992 ◽  
Vol 284 (3) ◽  
pp. 629-632 ◽  
Author(s):  
A Mauviel ◽  
C H Evans ◽  
J Uitto
Keyword(s):  
Gene Expression ◽  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Promoter Activity ◽  
Type I Collagen ◽  
Transforming Growth Factor ◽  
Dermal Fibroblasts ◽  
Type I ◽  
Mrna Levels ◽  
Human Dermal Fibroblasts

Leukoregulin (LR), a T-cell-derived growth factor, modulates fibroblast functions in vitro [Mauviel, Rédini, Hartmann, Loyau & Pujol (1991) J. Cell Biol. 113, 1455-1462]. In the present study, incubation of human dermal fibroblasts with LR (0.1-2 units/ml) resulted in decreases in the mRNA steady-state levels for alpha 1(I), alpha 2(I) and alpha 1(III), but not alpha 2(V), collagen genes. LR also down-regulated alpha 2(I) collagen promoter activity in transient cell transfections of control cells as well as those incubated with transforming growth factor-beta, a potent up-regulator of collagen type I gene expression. Thus LR is a strong inhibitor of type I collagen gene expression, acting at the level of transcription.

Sign in / Sign up

Export Citation Format

Share Document